We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMDA
176
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$135K 0.02%
32,689
+1,660
+5% +$5.56K
GOSS icon
177
PUT
Gossamer Bio
GOSS
$82.9M
$129K 0.02%
+14,900
New +$144K
DFTX
178
Definium Therapeutics
DFTX
$5.78B
$118K 0.02%
7,064
+397
+6% +$6.89K
BTAI icon
179
BioXcel Therapeutics
BTAI
$24.9M
$113K 0.01%
339
+16
+5% +$4.64K
ORTX
180
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$110K 0.01%
15,561
+748
+5% +$7.33K
CMPX icon
181
Compass Therapeutics
CMPX
$344M
$100K 0.01%
74,171
+4,171
+6% +$8.62K
NVAX icon
182
Novavax
NVAX
$1.2B
$100K 0.01%
1,362
+79
+6% +$7.04K
AMYT
183
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$70K 0.01%
37,248
+3,117
+9% +$28.1K
ATNX
184
DELISTED
Athenex, Inc. Common Stock
ATNX
$68K 0.01%
4,002
+195
+5% +$3.82K
ACAD icon
185
Acadia Pharmaceuticals
ACAD
$4.43B
$46K 0.01%
1,882
+117
+7% +$2.83K
IGMS
186
DELISTED
IGM Biosciences
IGMS
$43K 0.01%
1,587
+87
+6% +$1.62K
TNGX icon
187
Tango Therapeutics
TNGX
$4.43B
$42K 0.01%
5,456
+276
+5% +$2.39K
TRAW icon
188
Traws Pharma
TRAW
$6.85M
$35K ﹤0.01%
759
+156
+26% +$7.23K
SLNO
189
DELISTED
Soleno Therapeutics
SLNO
$29K ﹤0.01%
8,564
+451
+6% +$2.33K
PDSB icon
190
PDS Biotechnology
PDSB
$38.4M
$22K ﹤0.01%
3,672
+177
+5% +$1.1K
KNTE
191
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$22K ﹤0.01%
1,990
– –
TGTX icon
192
TG Therapeutics
TGTX
$7.96B
$21K ﹤0.01%
2,292
-98,447
-98% -$1.14M
KPTI icon
193
Karyopharm Therapeutics
KPTI
$43.5M
$6K ﹤0.01%
55
+3
+6% +$374
BXRX
194
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$4K ﹤0.01%
74
+6
+9% +$1.11K
BLUE
195
DELISTED
bluebird bio
BLUE
$1K ﹤0.01%
15
+1
+7% +$132
TSVT
196
DELISTED
2seventy bio
TSVT
$1K ﹤0.01%
99
+6
+6% +$102
ALLK
197
CALL
DELISTED
Allakos
ALLK
– –
-218,000
Closed -$2.13M
ALLK
198
PUT
DELISTED
Allakos
ALLK
– –
-37,400
Closed -$366K
AVIR icon
199
CALL
Atea Pharmaceuticals
AVIR
$376M
– –
-116,600
Closed -$1.04M
BBIO icon
200
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-100,000
Closed -$1.67M
5 6 7
8
9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.